Last updated: 11/07/2018 16:58:51
A Dose Proportionality Study of Fluticasone Propionate from 50, 125, and 250mcg HFA Inhalers and Comparability to 125 and 250mcg CFC Inhalers
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Dose Proportionality Study of Fluticasone Propionate from 50, 125, and 250mcg HFA Inhalers and Comparability to 125 and 250mcg CFC Inhalers
Trial description: A Dose Proportionality Study of Fluticasone Propionate from 50, 125, and 250mcg HFA Inhalers and Comparability to 125 and 250mcg CFC Inhalers
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
From hydrofluoroalkane pressurized metered dose inhalers (pmdis) and comparability with chlorofluorocarbon pmdis. Kunka, R., Andrews, S., Pimazzoni, M., Callejas, S., Ziviani, L., Squassante, L., and Daley-Yates, P. T. Respir Med 2000; 94 Suppl B(S10-6
Kunka, S. Andrews, M. Pimazzoni, S. Callejas, L. Ziviani, L. Squassante and P.T Daley-Yates. Dose proportionality of fluticasone propionate from hydrofluoroalkane inhalers and comparability with chlorofluorocarbon inhalers.
R. Kunka, S. Andrews, M. Pimazzoni, S. Callejas, L. Ziviani, L. Squassante and P.T Daley-Yates. Resp Med 94 (Suppl B) 10-16,2000
R.L. Kunka, S. Andrews, M Pimazzoni, S Callejas, P.T. Daley-Yates, L. Ziviani and L. Squassante. Dose proportionality of fluticasone propionate from HFA inhalers and comparability with CFC inhalers. Am J Resp Crit Care Med 159(3): A630, 1999
Medical condition
Respiratory Disorders
Product
fluticasone propionate
Collaborators
Not applicable
Study date(s)
March 1998 to May 1998
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1998-20-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website